Tag: CSL – Seqirus
Australia extends life-saving antivenom partnership with PNG
Australia is bolstering its support for Papua New Guinea's health system by renewing its partnership, which includes supplying antivenom doses and training healthcare workers, for an additional three years until 2027.
CSL’s $800 million vaccine manufacturing facility in Melbourne nears completion
CSL Seqirus has reached a major milestone in the construction of its new cutting-edge manufacturing facility for vaccine and antivenom manufacturing.Â
TGA approves domestic manufacture of AstraZeneca vaccine
CSL has been given the nod by the Therapeutic Goods Administration (TGA) to commence the manufacture of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S) in Australia.
TGA’s...
Featured Article
Driving the future of smart energy: GridBeyond and ABB unveil new white paper on battery storage innovation
As industries adopt cleaner, more intelligent energy solutions, the ability to manage, store, and trade energy efficiently is increasingly vital to sustaining a competitive edge.
